Method for Treating Alzheimer's Disease
Summary
The USPTO published patent application US20260091109A1 disclosing a method for treating Alzheimer's disease using sequential administration of anti-amyloid beta monoclonal antibodies in increasing doses to reduce ARIA risk. The application, filed June 16, 2025, names James L. Ferrero, Leslie Lugene Williams, and Jeffrey Joseph Sevigny as inventors. This publication provides public notice of a pending patent application but creates no compliance obligations for third parties.
What changed
The USPTO published patent application US20260091109A1 disclosing a method for treating Alzheimer's disease by sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to a human patient. Preferred embodiments involve administering the antibody in increasing amounts over time to reduce susceptibility to amyloid related imaging abnormalities (ARIA). The application was filed June 16, 2025, and names James L. Ferrero, Leslie Lugene Williams, and Jeffrey Joseph Sevigny as inventors.
This is a patent application publication only. It provides public notice of a pending application but creates no compliance obligations for third parties. No action is required by pharmaceutical or biotechnology companies. Parties interested in the patent landscape for Alzheimer's treatments may review the application through USPTO records.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method for Treating Alzheimer's Disease
Application US20260091109A1 Kind: A1 Apr 02, 2026
Inventors
James L. Ferrero, Leslie Lugene Williams, Jeffrey Joseph Sevigny
Abstract
A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
CPC Classifications
A61K 39/3955 C07K 16/18 C07K 16/28 A61K 2039/505 A61K 2039/545
Filing Date
2025-06-16
Application No.
19239695
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.